Stock Scorecard
Stock Summary for Praxis Precision Medicines Inc (PRAX) - $269.02 as of 12/15/2025 8:57:34 AM EST
Total Score
6 out of 30
Safety Score
40 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for PRAX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for PRAX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for PRAX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for PRAX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for PRAX (40 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for PRAX
Financial Details for PRAX
Company Overview |
|
|---|---|
| Ticker | PRAX |
| Company Name | Praxis Precision Medicines Inc |
| Country | USA |
| Description | Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies to address central nervous system disorders arising from neuronal imbalance. Leveraging a unique scientific platform, Praxis is advancing a robust pipeline of novel treatments tailored to conditions with significant unmet medical needs. The company is committed to improving patient outcomes and quality of life, positioning itself as a leader in the biopharmaceutical landscape dedicated to transformative solutions in neurology. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/4/2026 |
Stock Price History |
|
| Last Day Price | 269.02 |
| Price 4 Years Ago | 295.50 |
| Last Day Price Updated | 12/15/2025 8:57:34 AM EST |
| Last Day Volume | 402,786 |
| Average Daily Volume | 984,748 |
| 52-Week High | 278.44 |
| 52-Week Low | 26.70 |
| Last Price to 52 Week Low | 907.57% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 50.57 |
| Sector PE | 95.45 |
| 5-Year Average PE | -20.31 |
| Free Cash Flow Ratio | 44.99 |
| Industry Free Cash Flow Ratio | 16.39 |
| Sector Free Cash Flow Ratio | 29.98 |
| Current Ratio Most Recent Quarter | 5.18 |
| Total Cash Per Share | 5.98 |
| Book Value Per Share Most Recent Quarter | 16.23 |
| Price to Book Ratio | 19.46 |
| Industry Price to Book Ratio | 46.26 |
| Sector Price to Book Ratio | 41.48 |
| Price to Sales Ratio Twelve Trailing Months | 900.70 |
| Industry Price to Sales Ratio Twelve Trailing Months | 28.52 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.48 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 25,007,200 |
| Market Capitalization | 6,727,436,944 |
| Institutional Ownership | 96.08% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -48.30% |
| Reported EPS 12 Trailing Months | -12.98 |
| Reported EPS Past Year | -9.96 |
| Reported EPS Prior Year | -10.27 |
| Net Income Twelve Trailing Months | -273,036,000 |
| Net Income Past Year | -182,819,000 |
| Net Income Prior Year | -123,277,000 |
| Quarterly Revenue Growth YOY | 1,349.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | -3,928.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 149,527,000 |
| Total Cash Past Year | 215,372,000 |
| Total Cash Prior Year | 81,300,000 |
| Net Cash Position Most Recent Quarter | 149,527,000 |
| Net Cash Position Past Year | 215,372,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 445,450,000 |
| Total Stockholder Equity Prior Year | 69,669,000 |
| Total Stockholder Equity Most Recent Quarter | 343,505,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -228,427,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -9.13 |
| Free Cash Flow Past Year | -131,757,000 |
| Free Cash Flow Prior Year | -111,186,000 |
Options |
|
| Put/Call Ratio | 6.95 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 9.91 |
| MACD Signal | 12.82 |
| 20-Day Bollinger Lower Band | -30.50 |
| 20-Day Bollinger Middle Band | 103.06 |
| 20-Day Bollinger Upper Band | 236.61 |
| Beta | 2.98 |
| RSI | 56.04 |
| 50-Day SMA | 69.22 |
| 150-Day SMA | 48.54 |
| 200-Day SMA | 56.68 |
System |
|
| Modified | 12/13/2025 7:38:12 AM EST |